Filing Flows › Comparisons › ASBP vs AVTX
Aspire-Lakewood Holdings vs Avalo Therapeutics: ASBP and AVTX compared
Aspire-Lakewood Holdings is the larger company: $63K of revenue in its latest quarter (Q2 2026) against $59K for Avalo Therapeutics (Q4 2025).
Where the money goes: ASBP and AVTX
Aspire-Lakewood Holdings (ASBP) · Q2 2026
Aspire-Lakewood Holdings, Q2 2026: revenue $63K, net loss $1.3M, operating cash flow −$2.1M. The chart follows the revenue to costs, profit and cash.
Avalo Therapeutics (AVTX) · Q4 2025
Avalo Therapeutics, Q4 2025: revenue $59K (-69% year over year), net loss $13.7M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
| Aspire-Lakewood Holdings (ASBP) | Avalo Therapeutics (AVTX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q4 2025 |
| Revenue | $63K | $59K |
| Revenue growth, Y/Y | — | -69% |
| Operating margin | n/m | n/m |
| Net earnings | −$1.3M | −$13.7M |
| Operating cash flow | −$2.1M | −$14.2M |
| Market value | — | $595M |
| Analysts’ mean target | — | $36.60 |
Questions
Which is bigger, Aspire-Lakewood Holdings or Avalo Therapeutics?
Aspire-Lakewood Holdings is the larger company: $63K of revenue in its latest quarter (Q2 2026) against $59K for Avalo Therapeutics (Q4 2025).
More: Aspire-Lakewood Holdings earnings · how Aspire-Lakewood Holdings makes money · Avalo Therapeutics earnings · how Avalo Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-K filed Mar 23, 2026). Fiscal quarters can end on different dates. Not investment advice.